论文部分内容阅读
目的观察长效干扰素联合恩替卡韦治疗慢性乙型肝炎的疗效及对免疫功能的影响。方法选取医院2015年1月-2016年4月收治的慢性乙型肝炎患者76例为研究对象,依据随机数字表法分为观察组38例和对照组38例,对照组给予恩替卡韦治疗,观察组在对照组治疗的基础上给予长效干扰素治疗,观察治疗3、6、12个月后患者HBV-DNA转阴率及治疗前后免疫功能指标。结果治疗3、6个月后,2组HBV-DNA转阴率比较差异均无统计学意义(P>0.05);治疗12个月后,观察组HBV-DNA转阴率为76.32%高于对照组的52.63%,差异有统计学意义(P<0.05)。治疗前2组免疫功能指标比较差异无统计学意义(P>0.05),治疗12个月后观察组CD_3~+、CD_4~+、CD_4~+/CD_8~+均高于对照组,CD_8~+低于对照组,差异均有统计学意义(P<0.05)。结论长效干扰素联合恩替卡韦治疗慢性乙型肝炎效果显著,可明显改善患者免疫功能,值得临床推广。
Objective To observe the efficacy of long-acting interferon combined with entecavir in the treatment of chronic hepatitis B and its influence on immune function. Methods A total of 76 patients with chronic hepatitis B admitted from January 2015 to April 2016 in our hospital were enrolled in this study. According to the random number table, 38 patients in the observation group and 38 in the control group were enrolled. The control group was treated with entecavir. The observation group Long-term interferon treatment was given on the basis of the control group, and the negative rate of HBV-DNA and immune function before and after treatment were observed at 3, 6, and 12 months after treatment. Results After treatment for 3 and 6 months, there was no significant difference in the negative rates of HBV-DNA between the two groups (P> 0.05). After 12 months of treatment, the negative rate of HBV-DNA in the observation group was 76.32% Group, 52.63%, the difference was statistically significant (P <0.05). There was no significant difference in immune function between the two groups before treatment (P> 0.05). After 12 months treatment, CD_3 ~ +, CD_4 ~ + and CD_4 ~ + / CD_8 ~ + in the observation group were higher than those in the control group Lower than the control group, the difference was statistically significant (P <0.05). Conclusion Long-acting interferon combined with entecavir treatment of chronic hepatitis B effect is significant, can significantly improve the patient’s immune function, worthy of clinical promotion.